Skip to content
Axcess News – Lifestyle
Author:
Disc Medicine Inc
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
June 12, 2026
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
June 9, 2026
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2026
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
June 1, 2026
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
May 12, 2026
Disc Medicine to Participate in Upcoming Investor Conferences
May 11, 2026
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 21, 2026
FDA Issues Landmark Biosimilar Guidance Incorporating Regulatory Reforms Advised by Professor Niazi: Further Cutting Development Costs by Up to 50%
March 10, 2026
Disc Medicine to Participate in Upcoming Investor Conferences
March 5, 2026